Hikma announces exclusive agreement with AFT Pharmaceuticals for injectable non-opioid pain medication Combogesic® IV in the US

London, April 28, 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.

Press Release Corporate 28 April 2021

text

The licensing agreement provides Hikma with exclusive rights for the sales, marketing and distribution of Combogesic® IV in the US.  Combogesic® IV (paracetamol 1000mg + ibuprofen 300mg solution for infusion) is a patented intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally. AFT expects to file Combogesic® IV for approval with the US FDA in the coming months.

“We are pleased to enter into this partnership with AFT for Combogesic® IV, an important alternative for the treatment of post-operative pain,” said Riad Mishlawi, President, Hikma Injectables. “This agreement is another example of how Hikma is continuing to expand its pipeline in growing therapeutic areas like non-opioid pain management treatments, and highlights the importance of partnerships  in expanding our ability to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.